Biomarkers.

Background: Tau-PET tracers allow for in vivo Braak staging of individuals in the Alzheimer's disease (AD) continuum. The impact of tracers' characteristics for Braak staging using tau-PET remains unclear. Therefore, we performed a head-to-head comparison of Braak staging using first- and second-generation tau-PET tracers.

Biomarkers.

Background: Increased uptake on Tau positron-emission tomography (PET) is sometimes observed in the absence of amyloid β accumulation. This A-T+ PET profile might represent primary age-related tauopathy (PART), an amyloid β-independent 3R/4R tauopathy observed in aging brains. Although A-T+ individuals have been shown to follow a different cognitive trajectory compared to A-T- and A+T+ individuals, it remains unknown how they differ in terms of plasma biomarkers.

Biomarkers.

Background: Tau burden has been found to be involved in brain atrophy during aging, especially in regions such as the parahippocampal gyrus. However, how tau levels at baseline are associated with trajectories of tau accumulation, cortical thinning and cognitive impairment remains poorly understood. The goal of this study was to assess tau rate of change in patients between baseline Tau+ and Tau- patients.

Biomarkers.

Background: It has been proposed that microglia release of proinflammatory factors reactive to amyloid plaques constitutes an early event leading to tau pathology. Here, we assessed how the rate of progression of tau-PET and the rate of change in plasma pTau217 are affected by baseline levels of amyloid-β and neuroinflammation.

Methods: We included 93 individuals from TRIAD cohort: 11 young individuals, 57 cognitively unimpaired elderlies, 15 with mild cognitive impairment and 10 individuals with Alzheimer's Disease.

Biomarkers.

Background: Biomarkers promise to significantly improve the differential diagnosis of Alzheimer's disease (AD). Plasma biomarkers, such as phosphorylated tau (p-tau), have shown potential in diagnosing AD with high accuracy. Unlike the widely-used [18 F]FDG-PET diagnostic biomarker in clinical practice, plasma p-tau is specific to AD and can provide an affordable and scalable diagnostic tool.